Clinical Trials Logo

Filter by:
NCT ID: NCT03215706 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

CheckMate 9LA
Start date: August 24, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease

NCT ID: NCT03215511 Completed - Clinical trials for Solid Tumors Harboring NTRK Fusion

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Start date: July 3, 2017
Phase: Phase 1
Study type: Interventional

This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study also investigates how the drug is absorbed and processed in the human body, and how well and for how long the cancer responds to the drug. This is the first study to test selitrectinib in humans with cancer, for whom no other effective therapy exists.

NCT ID: NCT03215030 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

iinnovate-1
Start date: October 4, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants. Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa. Participants will receive modakafusp alfa at one of two doses which will be given through a vein.

NCT ID: NCT03214380 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

PRONTO-T2D
Start date: July 14, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).

NCT ID: NCT03214367 Completed - Clinical trials for Type 1 Diabetes Mellitus

A Study of LY900014 in Participants With Type 1 Diabetes

PRONTO-T1D
Start date: July 17, 2017
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).

NCT ID: NCT03213795 Completed - Clinical trials for Thoracoabdominal Aneurysms and Para-renal Aortic Aneurysms

Anatomical Feasibility of Multibranched Off-the-shelf Endografts for Thoracoabdominal and Para-renal Aortic Aneurysms (TAMBE Study)

TAMBE
Start date: April 12, 2017
Phase:
Study type: Observational

Since the development of multibranched endografts a novel therapeutic option for the management of thoracoabdominal and para-renal aortic aneurysms was made accessible. The introduction of readily available off-the-shelf devices expanded the application of such technology also to those patients who could not afford to wait for a customized endograft to be designed and manufactured according to their aneurysm morphology

NCT ID: NCT03213301 Completed - Clinical trials for Malignant Pleural Mesothelioma, Advanced

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Start date: September 28, 2017
Phase: Phase 2
Study type: Interventional

Aim of this study is to provide the "proof of concept" of efficacy and tolerability of lurbinectedin monotherapy in progressive malignant mesotheliomas.

NCT ID: NCT03212391 Recruiting - Hypertension Clinical Trials

WAVE Study- Walking and Aging in VErona Study

WAVE
Start date: September 19, 2016
Phase: N/A
Study type: Interventional

Monocentric unblinded two parallel-group randomized controlled trial to evaluate the effect of diet with or without Nordic Walking on weight loss, physical performance and cardiovascular risk factors in overweight and obese population

NCT ID: NCT03212248 Completed - Clinical trials for Community-acquired Pneumonia

CRP and Thoracic Emergency Ultrasound in Pneumonia

TUS-STRAT
Start date: January 2, 2016
Phase: N/A
Study type: Observational

This preliminary study investigates in patients with possible clinical diagnosis of pneumonia, clues and biomarker assessed at Emergency Department (ED) triage, potentially predicting detection of lung consolidation by Thoracic-ultrasound (TUS) and/or by Chest-X-Rays. Cough and high admission CRP levels will be defined according to the cutoff defined by ROC analysis, will be challenged if independently associated with TUS lung consolidation detection High level of the chosen biomarker, and any of the considered symptoms, in otherwise not extremely critical patients (CURB65≤3), should prompt to immediate confirm by TUS, during the physical examination. This may limit the need of further radiological investigations allowing targeted workup.

NCT ID: NCT03212196 Completed - Pancreatic Fistula Clinical Trials

Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant

PREP
Start date: June 12, 2017
Phase: N/A
Study type: Interventional

This trial will investigate what surgical technique between pancreaticogastrostomy and pancreaticojejunostomy with transanastomotic externalized drains is associated with the lowest rate of pancreatic fistula after pancreaticoduodenectomy in case of high-risk pancreatic remnants.